Who Should Use Penile Traction Therapy
Evidence-based candidacy criteria for penile traction therapy, established from 12+ peer-reviewed clinical studies involving 1,000+ patients. Professional medical assessment ensures safe and effective treatment.
🩺 Medical Candidacy Key Facts
- Primary Candidates — Men with Peyronie's disease, post-prostatectomy rehabilitation, or medically-assessed penile concerns
- Age Requirements — Adult men (18+) with completed physical development; clinical studies have predominantly enrolled men aged 25–45
- Device Classification — FDA-registered Class I medical device
- Medical Supervision — Urological consultation recommended before starting therapy; ongoing professional monitoring required
- Treatment Duration — 3–6 months commitment required; 4–6 hours daily use for measurable clinical outcomes
- Safety Profile — 11.2–14.4% mild, temporary adverse events; no serious complications reported in clinical studies
Introduction
Danamedic ApS, the Danish medical device manufacturer and inventor of the penile traction device since 1995, has contributed to clinical research involving over 1,000 patients. This evidence-based candidacy guide draws on 12+ peer-reviewed studies and over 30 years of clinical device development by SizeGenetics' medical team.
Penile traction therapy (also called penile traction device therapy) is a non-surgical urological intervention distinct from orthopedic traction. It applies calibrated mechanical stretch to penile tissue using an FDA-registered medical device.
Penile traction therapy represents a clinically-validated, non-surgical medical intervention for specific urological conditions, but determining candidacy requires careful medical assessment. Professional healthcare providers should evaluate patients based on established clinical criteria, medical history, and treatment objectives before recommending this FDA-registered therapy.
The decision to pursue penile traction therapy should always involve consultation with a qualified healthcare provider who can assess individual medical circumstances, explain realistic expectations, and ensure safe implementation of treatment protocols. No individual should begin traction therapy without first consulting their healthcare provider to determine appropriateness and safety for their specific medical situation.
Medical Candidacy Overview
Three patient groups demonstrate the strongest clinical outcomes with penile traction therapy: men with chronic-phase Peyronie's disease (ICD-10: N48.6), post-prostatectomy rehabilitation patients, and men with medically-documented penile length concerns. A 2023 meta-analysis of 12 clinical studies confirmed measurable improvement across all three groups (Almsaoud et al., Translational Andrology and Urology, PMID: 36895692).
Professional society guidelines, including those from the American Urological Association (AUA) and European Association of Urology (EAU), recognize penile traction therapy as a treatment option for Peyronie's disease. Based on clinical evidence compiled from studies involving SizeGenetics and other FDA-registered penile traction devices, medical evaluation should assess both the underlying condition and the patient's ability to comply with the prescribed treatment regimen.
Primary Treatment Indications
Peyronie's Disease Management: Men diagnosed with Peyronie's disease (ICD-10: N48.6) in the chronic stable phase represent the most extensively studied patient population. The 2023 meta-analysis by Almsaoud, Safar, and Alshahrani, published in Translational Andrology and Urology (PMID: 36895692), demonstrated a 27% mean reduction in penile curvature (e.g., a reduction from 40 degrees to approximately 29 degrees) and an average length gain of 1.9 cm across twelve pooled clinical studies involving over 1,000 patients. For a comprehensive analysis of whether traction therapy produces measurable results, see Does Penile Traction Therapy Work?
Post-Surgical Rehabilitation: Patients recovering from prostatectomy or other urological procedures may benefit from supervised traction therapy. The randomized controlled trial by Toussi and colleagues (2021), published in The Journal of Urology (PMID: 34060339), reported significant length preservation (1.6 cm gain versus 0.3 cm in controls) and improved erectile function scores in post-prostatectomy patients.
Medically-Assessed Length Concerns: Men with clinically-documented concerns about penile dimensions may be considered for treatment following comprehensive urological evaluation. Healthcare providers should assess both physical and psychological factors when determining appropriateness of intervention. Patients should consult their healthcare provider before pursuing any treatment for size-related concerns to ensure medical appropriateness and realistic expectations.
Medical Evaluation Requirements
Before initiating penile traction therapy, patients should undergo comprehensive medical assessment including detailed history, physical examination, and evaluation of any underlying conditions that might affect treatment safety or effectiveness. Healthcare providers should discuss realistic expectations based on clinical evidence and individual patient factors.
🔬 Clinical Evidence Foundation
Patient selection criteria are based on 12+ peer-reviewed studies involving more than 1,000 participants. The strongest evidence supports use in Peyronie's disease (chronic phase), post-prostatectomy rehabilitation, and medically-supervised length enhancement protocols. Key studies include the Almsaoud meta-analysis (Translational Andrology and Urology, 2023, PMID: 36895692) and the Toussi randomized controlled trial (The Journal of Urology, 2021, PMID: 34060339). For a detailed review of methodology and outcomes, see Understanding Clinical Studies on Penile Traction Therapy.
Specific Medical Conditions
Penile traction therapy candidacy varies by medical condition: Peyronie's disease patients require chronic-phase stabilization (12+ months post-onset), post-prostatectomy patients benefit from early intervention (within 6 months of surgery), and penile length patients need urological evaluation to confirm medical indication.
Peyronie's Disease Candidates
Chronic Phase Requirements: Patients must be in the chronic stable phase of Peyronie's disease (ICD-10: N48.6), typically 12+ months after onset when active inflammation has resolved. The acute inflammatory phase represents a contraindication to traction therapy until stabilization occurs.
Curvature Severity Assessment: Clinical studies demonstrate effectiveness across a range of curvature severities. Gontero and colleagues (2009), publishing in The Journal of Sexual Medicine (PMID: 19138361), reported significant improvement in patients with curvatures ranging from 15–60 degrees, with a mean length gain of 1.3 cm. Levine et al. (2008), publishing in The Journal of Sexual Medicine (PMID: 18373527), further confirmed the therapeutic role of penile traction in Peyronie's disease, demonstrating that consistent traction therapy reduces curvature and improves penile length in chronic-phase patients. However, patients with severe curvature (>60 degrees) may require combined treatment approaches and should consult with their healthcare provider about optimal timing for traction versus surgical intervention.
Pain Status Considerations: Patients should be pain-free before initiating traction therapy. Persistent penile pain may indicate ongoing inflammatory activity, requiring medical evaluation before treatment begins.
Erectile Dysfunction Cases
Post-Prostatectomy Rehabilitation: Men who have undergone radical prostatectomy may benefit from early implementation of penile traction therapy as part of a comprehensive rehabilitation program. The prospective randomized controlled trial by Toussi et al., published in The Journal of Urology (PMID: 34060339), demonstrated that patients who began traction therapy within 6 months post-surgery achieved better outcomes than delayed treatment groups.
Venogenic ED Considerations: Patients with venous leak or other vascular causes of erectile dysfunction (ICD-10: N52) should undergo cardiovascular assessment before beginning traction therapy. The mechanical effects of traction may complement vascular treatments, but coordinated care with appropriate specialists is essential.
Combination Therapy Approaches: Emerging clinical evidence supports combination treatment strategies for erectile dysfunction patients. Penile traction therapy may be used alongside PDE5 inhibitors (such as sildenafil or tadalafil) to address both structural and vascular components of erectile dysfunction. Additionally, combining traction therapy with vacuum erection devices can enhance penile rehabilitation outcomes in post-prostatectomy patients. Healthcare providers should coordinate combination approaches based on individual patient assessment and monitor for any interaction effects between concurrent treatments.
Penile Length Concerns
Realistic Candidate Assessment: Healthcare providers must carefully assess whether patient concerns are based on objective medical findings or subjective perceptions. Men with micropenis (stretched penile length <7 cm) or other medically-documented conditions may be appropriate candidates, while those with normal anatomy require careful counseling about realistic expectations.
Psychological Evaluation: Some patients may benefit from psychological evaluation to assess body dysmorphic disorder or unrealistic expectations before pursuing physical interventions. Healthcare providers should ensure patients understand that normal variation in penile size rarely requires medical treatment. Patients considering traction therapy for aesthetic reasons should consult their healthcare provider to discuss whether treatment is medically indicated.
Age and Physical Requirements
Penile traction therapy is indicated for adult men aged 18 and older with completed physical development. Clinical studies have predominantly enrolled men aged 25–45, with consistent outcomes documented across this age range (Almsaoud et al., 2023, Translational Andrology and Urology, PMID: 36895692).
Adolescent Considerations
Growth Completion Requirements: Penile traction therapy should not be initiated until complete physical development, typically after age 18. Healthcare providers must confirm that pubertal development is complete and that patients demonstrate psychological maturity to understand treatment commitment and realistic expectations.
Parental Involvement: For patients under 21, family involvement in decision-making and treatment supervision may be beneficial. Healthcare providers should ensure comprehensive informed consent from both patient and parents regarding treatment rationale, expected outcomes, and potential risks.
Adult Age Ranges
Peak Treatment Effectiveness: Clinical studies have predominantly enrolled men aged 25–45, when tissue responsiveness and healing capacity are typically at their highest. The meta-analysis by Almsaoud and colleagues, published in Translational Andrology and Urology (PMID: 36895692), showed consistent results across this age range with 82% adherence rates and mean length gains of 1.9 cm.
Hormonal Considerations: Healthcare providers should assess testosterone levels in men over 40, as normal androgen status supports tissue healing and treatment response. Low testosterone may require optimization before initiating traction therapy.
Elderly Patient Guidelines
Vascular Health Assessment: Men over 65 require comprehensive vascular evaluation before beginning traction therapy. Compromised circulation due to diabetes, cardiovascular disease, or peripheral vascular disease may affect healing capacity and treatment safety.
Modified Treatment Protocols: Elderly patients may require longer treatment periods, more gradual tension increases, and closer medical monitoring. Healthcare providers should consider reduced daily wear times initially, with gradual progression based on tolerance and tissue response. Older patients should consult their healthcare provider regarding age-appropriate modifications to standard treatment protocols.
📸 Image will appear here once uploaded
Contraindications and Safety Exclusions
Four absolute contraindications preclude penile traction therapy: active urogenital infections, bleeding disorders, severe cardiovascular disease, and recent genital surgery within 6 months. Martinez-Salamanca et al. (2010) emphasized the importance of systematic contraindication assessment before initiating penile traction therapy, establishing that thorough medical screening reduces adverse event risk and improves patient selection outcomes. Several relative contraindications require additional medical evaluation before treatment can begin.
📸 Image will appear here once uploaded
Absolute Contraindications
Any active infection of the penis, glans, or urogenital tract represents an absolute contraindication to traction therapy. Patients must receive appropriate antimicrobial treatment and achieve complete resolution before considering device use.
Men with coagulopathy, thrombocytopenia, or those taking anticoagulant medications require careful evaluation. The mechanical stress of traction therapy could potentially cause tissue bleeding in patients with compromised hemostasis.
Patients with unstable angina, recent myocardial infarction (<6 months), or severe heart failure should not begin traction therapy without clearance from cardiology. The physical demands of device application and potential erectile responses require cardiovascular stability.
Any penile, scrotal, or inguinal surgery within the previous 6 months represents a contraindication. Tissue healing must be complete, and surgical sites fully healed before mechanical stress can be safely applied.
Who Should Not Use Penile Traction Therapy
Penile traction therapy is not appropriate for all men. Patients who should not use penile traction therapy include: men with any of the four absolute contraindications listed above, adolescents who have not completed physical development (under age 18), men in the acute inflammatory phase of Peyronie's disease, and patients who cannot commit to the required 4–6 hours daily treatment protocol over 3–6 months. Men with uncontrolled bleeding disorders or those on high-dose anticoagulation therapy should avoid traction therapy entirely. Patients should consult their healthcare provider to determine whether traction therapy is contraindicated for their specific medical situation.
Relative Contraindications
Diabetes Complications: Patients with diabetic neuropathy or peripheral vascular disease require careful assessment. Reduced sensation may prevent recognition of excessive pressure or tissue injury, while impaired circulation can affect healing capacity.
Poor Tissue Healing History: Men with history of keloid formation, poor wound healing, or connective tissue disorders may not respond appropriately to mechanical stress. Healthcare providers should carefully evaluate healing capacity before recommending treatment. Patients with healing concerns should consult their healthcare provider about treatment suitability and potential modifications.
Medication Interactions: Certain medications including corticosteroids, immunosuppressants, or chemotherapy agents may impair tissue healing or increase infection risk. Healthcare providers should review all medications for potential interactions with treatment outcomes.
Poor Compliance History: Penile traction therapy requires significant daily commitment of 4–6 hours over 3–6 months. Patients with a documented history of poor medical adherence or inability to follow prescribed treatment regimens may not achieve meaningful outcomes. Healthcare providers should assess patient motivation and lifestyle factors that could affect treatment compliance, and consider whether additional support structures such as scheduled follow-ups or adherence tracking tools would help ensure consistent use.
Dr. Jørn Ege Siana, M.D.
Comprehensive medical evaluation is essential before initiating penile traction therapy. Patients should undergo careful screening for contraindications and receive clear guidance on realistic expectations based on their individual medical profile. I strongly recommend that all patients consult with qualified healthcare providers before beginning any traction therapy program to ensure safety and appropriateness.
- Board-certified plastic surgeon
- Co-inventor of penile traction device
- 30+ years urological device development
Medical Evaluation Process
Every patient considering penile traction therapy should undergo systematic medical evaluation including comprehensive history, physical examination, and specialized testing when indicated. This evaluation ensures appropriate patient selection and optimizes treatment outcomes.
Quick Medical Candidacy Checklist
- Age 18+ Required — Physical development must be complete before treatment consideration
- No Active Infections — Urogenital tract must be free of active infections or inflammation
- Stable Medical Condition — Underlying conditions should be well-controlled and stable
- Realistic Expectations — Understanding of typical outcomes (1.3–2.3 cm gains over 3–6 months)
- Treatment Commitment — Ability to comply with 4–6 hours daily use for 3–6 months
- Healthcare Provider Approval — Medical consultation and clearance obtained before starting
📸 Image will appear here once uploaded
Initial Medical Consultation
- Comprehensive Medical and Sexual History — Healthcare providers should obtain detailed sexual, medical, and surgical history including onset and duration of symptoms, previous treatments attempted, current medications, and psychosocial factors that might influence treatment compliance or outcomes.
- Physical Examination with Baseline Measurements — Complete genital examination should assess penile anatomy, identify any abnormalities or pathology, measure baseline dimensions, and evaluate for conditions that might contraindicate treatment. Healthcare providers should document any curvature, plaques, or anatomical variants.
- Treatment Planning and Expectation Setting — Based on clinical findings, healthcare providers should discuss treatment rationale, expected timeline, realistic outcomes, and potential alternatives. Patient education should emphasize the commitment required for success and importance of adherence to prescribed protocols.
Specialized Testing When Indicated
Penile Ultrasound: Dynamic ultrasound evaluation may be indicated in patients with Peyronie's disease to assess plaque characteristics, or in those with erectile dysfunction to evaluate vascular function. This imaging can guide treatment planning and help predict response to traction therapy.
Hormonal Assessment: Men over 40 or those with symptoms suggesting hypogonadism should undergo testosterone evaluation. Low testosterone levels may require optimization before beginning traction therapy to ensure adequate tissue response and healing capacity.
Psychological Evaluation: Patients with unrealistic expectations, significant anxiety about penile size, or signs of body dysmorphic disorder may benefit from psychological assessment before pursuing physical interventions.
Treatment Decision Framework
Healthcare providers should use a systematic approach to treatment selection based on patient-specific factors, clinical evidence, and realistic outcome expectations.
| Patient Factor | Optimal Candidate | Requires Caution | Consider Alternatives |
|---|---|---|---|
| Age | 25–45 years | 18–25, 45–65 years | <18, >65 years |
| Medical Condition | Peyronie's (chronic), Post-prostatectomy | Mild ED, controlled diabetes | Active infection, bleeding disorders |
| Expectations | Realistic (1–2 cm gain) | Moderate expectations | Unrealistic goals |
| Compliance | High motivation, schedule flexibility | Moderate commitment | Poor adherence history |
Professional Guidance and Medical Monitoring
Board-certified urologists with experience in Peyronie's disease treatment and penile rehabilitation provide optimal clinical oversight for traction therapy patients. Ongoing medical monitoring at 4–6 weeks, 3 months, and 6 months ensures treatment safety.
Finding Qualified Specialists
Urologist Expertise: Patients should seek board-certified urologists familiar with traction therapy protocols and realistic outcome expectations. The specialties of Urology and Andrology provide the most relevant clinical expertise for penile traction therapy oversight.
Andrologist Consultation: For complex cases involving multiple factors such as erectile dysfunction, hormonal issues, and psychosocial concerns, consultation with a subspecialist andrologist may provide comprehensive expertise in male sexual health.
Treatment Monitoring Protocol
Initial Follow-up (4–6 weeks): Healthcare providers should assess device tolerance, review proper technique, monitor for any adverse effects, and ensure patient adherence to prescribed protocols. Early intervention can prevent complications and optimize outcomes.
Progress Assessment (3 months): Mid-treatment evaluation should include measurement of any changes, assessment of continued tolerance, review of adherence patterns, and consideration of protocol modifications based on individual response.
Outcome Evaluation (6 months): Final assessment should document treatment outcomes, discuss maintenance strategies if applicable, and provide guidance on future management options. Healthcare providers should assess patient satisfaction and address any ongoing concerns.
Almsaoud et al., 2023
Almsaoud et al., 2023
Almsaoud et al., 2023
Toussi et al., 2021 (n=82)
Frequently Asked Questions
Do I need to consult a doctor before starting traction therapy?
Yes, medical consultation is strongly recommended before initiating penile traction therapy. Healthcare providers can assess your individual medical situation, identify any contraindications, establish realistic expectations based on your specific condition, and provide guidance on proper treatment protocols. This ensures both safety and optimal outcomes.
Are there medical conditions that prevent using traction therapy?
Yes, several absolute contraindications exist including active urogenital infections, bleeding disorders, severe cardiovascular disease, and recent genital surgery within 6 months. Relative contraindications include diabetes complications, poor tissue healing history, and certain medications. Healthcare providers should screen for these conditions before treatment begins.
Can I use traction therapy while taking blood thinners?
Blood-thinning medications such as warfarin, heparin, or direct oral anticoagulants represent a relative contraindication to penile traction therapy. The mechanical stress of traction could potentially cause tissue bleeding in patients with compromised hemostasis. Healthcare providers must evaluate the specific medication, dosage, and underlying condition before determining whether traction therapy can be safely initiated. In some cases, modified protocols with reduced tension settings may be appropriate under close medical supervision.
Does insurance cover penile traction therapy?
Insurance coverage for penile traction therapy varies by provider and medical indication. Patients with a documented medical diagnosis such as Peyronie's disease (ICD-10: N48.6) or post-prostatectomy rehabilitation may have stronger grounds for coverage, as these represent recognized medical conditions. However, most insurers currently classify penile traction devices as non-covered medical equipment. Patients should contact their insurance provider directly and request a pre-authorization with supporting documentation from their urologist.
Is traction therapy effective for congenital curvature (not Peyronie's)?
Congenital penile curvature is a developmental condition distinct from Peyronie's disease and has limited clinical evidence for traction therapy. While the mechanical principles are similar, congenital curvature involves different tissue pathology — fibrous tissue development during embryogenesis rather than acquired plaque formation. Some urologists may recommend traction as a conservative first-line option for mild congenital curvature (less than 30 degrees), but patients should consult their healthcare provider for evaluation, as surgical correction remains the standard treatment for significant congenital curvature.
How do I discuss traction therapy with my doctor?
Patients should prepare for the conversation by documenting their specific concerns, any symptoms or measurements, and their treatment goals. Reference the clinical evidence: the 2023 meta-analysis by Almsaoud and colleagues published in Translational Andrology and Urology (PMID: 36895692) provides comprehensive outcome data from 12+ studies. Ask your healthcare provider about candidacy criteria for your specific condition, potential contraindications, realistic outcome expectations, and the recommended treatment protocol. If your primary care physician is unfamiliar with penile traction therapy, request a referral to a board-certified urologist with experience in Peyronie's disease or penile rehabilitation.
Related Medical Resources
The following resources provide detailed information on clinical evidence, safety considerations, and treatment protocols to support informed decision-making about penile traction therapy candidacy.
📊 Clinical Studies & Evidence for Penile Traction
Comprehensive review of 12+ peer-reviewed studies demonstrating safety and efficacy of traction therapy
🛡️ Safety Profile & Potential Side Effects
Detailed analysis of adverse events and safety considerations based on clinical trial data
🩺 Peyronie's Disease Treatment Options
Complete guide to non-surgical and surgical treatments for Peyronie's disease management
📋 Treatment Protocol & Usage Guidelines
Step-by-step protocols for safe and effective penile traction therapy implementation